eau,aua靶向治疗新进展-powerpointte资料.pptVIP

接受靶向药物治疗患者是否需要肾切除手术? 是否能用靶向治疗筛选可能受益于手术治疗的晚期肾癌患者? Conclusions Sunitinib demonstrated antitumour activity in both patients with or without prior Nx for whom baseline metastatic disease burden was similar in both groups. ? However, as might be expected, outcome to sunitinib treatment favoured patients with prior Nx. ? Sunitinib: EORTC-GU III 期临床研究 Sunitinib 和肾切除手术 靶向治疗评估sunitnib治疗后分子标志物 77% of the response could be predicted: if VEGF difference was observed, 80% of patients had clinical response. But if VEGF surexpression was absent 70% of the patients had no clinical response.